CA3077749A1 - Srpk1 inhibitors - Google Patents
Srpk1 inhibitors Download PDFInfo
- Publication number
- CA3077749A1 CA3077749A1 CA3077749A CA3077749A CA3077749A1 CA 3077749 A1 CA3077749 A1 CA 3077749A1 CA 3077749 A CA3077749 A CA 3077749A CA 3077749 A CA3077749 A CA 3077749A CA 3077749 A1 CA3077749 A1 CA 3077749A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- compound
- hydrogen
- cyclopropyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1715637.3A GB201715637D0 (en) | 2017-09-27 | 2017-09-27 | SRPK1 Inhibitors |
| GB1715637.3 | 2017-09-27 | ||
| GB1810765.6 | 2018-06-29 | ||
| GBGB1810765.6A GB201810765D0 (en) | 2018-06-29 | 2018-06-29 | SRPK1 inhibitors |
| PCT/GB2018/052735 WO2019063996A1 (en) | 2017-09-27 | 2018-09-26 | INHIBITORS OF SRPK1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3077749A1 true CA3077749A1 (en) | 2019-04-04 |
Family
ID=63722692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077749A Pending CA3077749A1 (en) | 2017-09-27 | 2018-09-26 | Srpk1 inhibitors |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11420969B2 (https=) |
| EP (1) | EP3687990A1 (https=) |
| JP (1) | JP7261793B2 (https=) |
| CN (1) | CN111448193B (https=) |
| AU (1) | AU2018341084B2 (https=) |
| CA (1) | CA3077749A1 (https=) |
| WO (1) | WO2019063996A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3821947A1 (en) * | 2019-11-13 | 2021-05-19 | Libra Therapeutics, Inc. | Heterocyclic trpml1 agonists |
| GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| US20240221945A1 (en) * | 2023-01-03 | 2024-07-04 | Industry-Academic Cooperation Foundation, Yonsei University | Server and method for predicting incidence of moyamoya disease through learning of fundus image |
| CN120917015A (zh) * | 2023-01-20 | 2025-11-07 | 元启(苏州)生物制药有限公司 | Srpk1抑制剂和使用方法 |
| WO2025243082A2 (en) * | 2024-05-24 | 2025-11-27 | The Chinese University Of Hong Kong | Covalent protein-protein interaction inhibitor against srpks |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60235761D1 (de) | 2001-08-01 | 2010-05-06 | Univ Bristol Clifton | Isoform des vegfs |
| MXPA05011503A (es) * | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Inhibidores de la c-fms cinasa. |
| US7569536B2 (en) * | 2003-12-26 | 2009-08-04 | Masatoshi Hagiwara | Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| JP5349309B2 (ja) * | 2007-08-03 | 2013-11-20 | 株式会社キノファーマ | 抗ｄｎａウイルス作用を有するアニリン誘導体 |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| JP2012509306A (ja) | 2008-11-22 | 2012-04-19 | ザ ユニバーシティ オブ ブリストル | ＶＥＧＦｘｘｘｂの新規な使用 |
| WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| JP2016504270A (ja) * | 2012-10-17 | 2016-02-12 | ザ ユニバーシティ オブ ブリストル | 眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物 |
| GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
-
2018
- 2018-09-26 WO PCT/GB2018/052735 patent/WO2019063996A1/en not_active Ceased
- 2018-09-26 AU AU2018341084A patent/AU2018341084B2/en active Active
- 2018-09-26 EP EP18782140.0A patent/EP3687990A1/en active Pending
- 2018-09-26 JP JP2020517549A patent/JP7261793B2/ja active Active
- 2018-09-26 CA CA3077749A patent/CA3077749A1/en active Pending
- 2018-09-26 US US16/651,182 patent/US11420969B2/en active Active
- 2018-09-26 CN CN201880075104.5A patent/CN111448193B/zh active Active
-
2022
- 2022-08-04 US US17/880,925 patent/US12325704B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12325704B2 (en) | 2025-06-10 |
| CN111448193B (zh) | 2023-12-22 |
| JP7261793B2 (ja) | 2023-04-20 |
| US20220389015A1 (en) | 2022-12-08 |
| CN111448193A (zh) | 2020-07-24 |
| JP2020535172A (ja) | 2020-12-03 |
| AU2018341084B2 (en) | 2023-04-13 |
| US11420969B2 (en) | 2022-08-23 |
| WO2019063996A1 (en) | 2019-04-04 |
| US20200270249A1 (en) | 2020-08-27 |
| AU2018341084A1 (en) | 2020-04-23 |
| EP3687990A1 (en) | 2020-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12325704B2 (en) | SRPK1 inhibitors | |
| AU2017331345B2 (en) | Compounds and methods for IDO and TDO modulation, and indications therefor | |
| AU2016337309B2 (en) | Compounds | |
| AU2015248656B2 (en) | Piperazine derivatives for treating disorders | |
| AU2014204831A1 (en) | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | |
| CA3167675A1 (en) | Pyrazole derivatives | |
| JP2018203748A (ja) | 眼血管形成（ｏｃｕｌａｒ ｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物 | |
| IL292466B2 (en) | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(adp-ribose) polymerase-1-related diseases, comprising the same as active ingredient | |
| CN105916506A (zh) | 作为tam家族激酶抑制剂的喹唑啉衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230925 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240912 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240912 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240912 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241107 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250303 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250718 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250718 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251112 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260219 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260219 |